Serratiopeptidase · Serratia E-15
Serrapeptase (Serratiopeptidase) is a proteolytic enzyme originally isolated from the silkworm gut bacterium Serratia E-15 (now produced via fermentation). Used in Asia and Europe since the 1960s for inflammation, pain, and mucolytic applications. Available as pharmaceutical drug in Japan, Italy, and other countries; sold as dietary supplement in the US.
Starting dose. 60,000-120,000 SU daily
Empty stomach essential.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Serrapeptase is a 30 kDa metalloprotease:
Hydrolyzes mucus glycoproteins, thinning thick mucus secretions in sinusitis, bronchitis, cystic fibrosis.
Hydrolyzes bradykinin, fibrin, and inflammatory exudates - reduces edema and pain.
Breaks down fibrin (cross-linked protein) - mechanism for proposed cardiovascular plaque effects.
Stomach acid degrades serrapeptase. Enteric-coated tablets release in the alkaline small intestine for absorption.
Acts on dead/damaged tissue but spares healthy tissue - mechanism for safety profile.
Days 1-7: acute anti-inflammatory effects.
Weeks 1-4: peak effects.
Long-term: as needed.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
These applications are attributable to its versatile properties including anti-inflammatory, anti-biofilm, analgesic, anti-edemic, and fibrinolytic effects.
These applications are attributable to its versatile properties including anti-inflammatory, anti-biofilm, analgesic, anti-edemic, and fibrinolytic effects.
Serratiopeptidase: Insights into the therapeutic applications.
Evidence scope. Narrative review; does not validate enteric absorption or the displayed SU dose.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 60,000-120,000 SU daily via Oral enteric-coated tablet, 1-3x daily. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.
Primary safety claim: Mild GI. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
Hours plasma
Post-ingestion (enteric)
Hours plasma; cumulative effects over weeks
Oral low without enteric coating (~0%); enteric-coated ~10-30%
Daily dosing for sustained effects
Hepatic and renal
Storage. Tablet. Cool dry location, refrigerate for extended storage.
Dietary supplement (US, DSHEA). Pharmaceutical drug in Japan, India, other Asian markets. EMA / Italy withdrew pharmaceutical status 2014.
Put it to work
Open Serrapeptase straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Serrapeptase in the app →Go deeper
The complete Serrapeptase walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.